This website uses cookies

We use cookies and website tracking tools to provide you with the best online experience. Learn more in our privacy statement.

if you accept, your choice will be valid until cancellation.

If you disallow cookies, functionality of our website might be limited.

 

Clinical Parkinson Research

Parkinson´s disease (PD) is the second most frequent neurodegenerative disorder after Alzheimer’s disease and affects about 1 to 2 % of individuals over the age of 65. The number is steadily increasing due to demographic changes in Western countries.

Clinically, most patients present with the cardinal motor symptoms of bradykinesia, resting tremor, rigidity, and postural instability but also suffer from a variety of non-motor symptoms such as autonomic dysfunction, depression, and hyposmia. However, the degree of progression shows a large variability with cognitive impairment as one major milestone of the disease.

Disease and Research Focus
Team
Outpatient Clinic
Publications

Parkinson's Disease

 

 Clinical Symptoms

 

Parkinson's disease (PD) is the second most frequent neurodegenerative disorder after Alzheimer’s disease and affects about 1 to 2 % of individuals over the age of 65. The number is steadily increasing due to demographic changes in Western countries.

Clinically, most patients present with the cardinal motor symptoms of bradykinesia, resting tremor, rigidity, and postural instability but also suffer from a variety of non-motor symptoms such as autonomic dysfunction, depression, hyposmia and cognitive impairment. 

Pathology

 

Underlying these clinical features is a progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc), accompanied by an accumulation of eosinophilic intracytoplasmic protein inclusions in surviving dopaminergic neurons, known as Lewy bodies and Lewy neuritis.

Prodromale Phase

 

Today we know that 40-60% of the dopaminergic neurons are already degenerated at the time when motor symptoms allow clinical diagnosis. This timespan in which neurodegeneration is proceeding without leading to classical motor symptoms is termed “prodromal phase of PD”. However, this phase is not inapparent. A variety of clinical non-motor symptoms may occur. They typically include, among others, constipation, olfactory dysfunction, sleep disorders (rapid eye movement behavior disorder and excessive daytime sleepiness), and neuropsychiatric symptoms such as depression and anxiety. The understanding of the prodromal phase of the disease may perspectively help to reliably identify at-risk individuals.

Milestones in the Disease Course

 

In the era where motor symptoms can be increasingly well controlled, dementia represents a key milestone in the course of PD. It is well known that, next to falls, dementia is one of the main predictors for the assignment to a nursing home and for death. However, the time course until reaching this milestone is highly variable. This calls for the identification of modifying factors which in turn might help to predict the course of the disease and possibly opens new therapeutic windows. Besides the quantification of clinical markers (neuropsychological scores, activity of daily living function), genetic variants and CSF profiles may help to define a high-risk group for Parkinson’s disease dementia at an early stage. These findings may have implications for future stratification and counseling of PD patients.

Genetics of Parkinson's Disease

 

Since twin studies in the 1980s failed to confirm evidence of familial aggregation, genetic factors were thought to play a minor role in the pathogenesis of PD. But nevertheless, PD patients with additionally affected relatives and PD families showing a typical pattern of inheritance were recognized. To date, we know of several genes causing either autosomal dominantly and autosomal recessively inherited forms of PD. More recently, advances in genetic technologies has allowed to focus on the contribution of gene variants to the development of the much more common sporadic form of PD. These variants are not directly disease causing but rather increase the risk for the development of PD. As the majority of these variants are not located in the coding regions of genes, their effect is most likely mediated by alterations of the regulation of gene expression.

The discovery of genes that are associated with Parkinson’s Disease has provided important insights into the molecular mechanisms underlying the disease. The major pathways to be discussed are mitochondrial and lysosomal dysfunction.  

Therapy

 

Current therapy is primarily symptomatic without effect on the disease-causing mechanisms. However, with the identification of genes that are associated with Parkinson’s disease, specific pathways underlying the pathophysiology in subgroups of patients have been discovered. These pathways include e.g. mitochondrial and lysosomal dysfunction as well as inflammatory patterns and represent the basis for new disease-causing and disease course-modifying treatment strategies. 

Focus of Research

 

Since Parkinson’s disease is a complex multifactorial disorder with a large variability in phenotypes and progression, our focus of research aims patient stratification according to clinical markers, imaging patterns, genetic architecture and, importantly, the underlying pathologic processes, possibly reflected by distinct profiles in patient biomaterials such as blood and cerebrospinal fluid. This in turn is a most needed prerequisite to introduce patients to pathway-specific milestone-related therapies.

In this context, special interest lies in genetically-associated forms of the disease such as patients carrying a mutation in the GBA or LRRK2 gene. Moreover, we focus on one of the most important milestone in the course of the disease, namely dementia. Next to pathophysiological aspects, we aim to evaluate risk factors and prodromal symptoms for the development of dementia as well as impact on quality of life.


 
Name
Research Group
Phone
Email
Dr. Kathrin Brockmann
Dr. Kathrin Brockmann Physician, Provisional Research Group Leader
Clinical Parkinsons Disease Research
 
 Christian Deuschle
Christian Deuschle Medical Technical Assistant
Clinical Parkinsons Disease Research
07071 29-82041 
Dr. Bettina Faust
Dr. Bettina Faust Research Group Coordination
Clinical Parkinsons Disease Research
07071 29-87637 
 Tanja Heger
Tanja Heger Medical Documentalist
Clinical Parkinsons Disease Research
07071 29-83621 
 Heiderose Heiss
Heiderose Heiss Study Assistant
Clinical Parkinsons Disease Research
 
 Ella Hilt
Ella Hilt study nurse
Clinical Parkinsons Disease Research
07071 29-85660 
Dr. Stefanie Lerche
Dr. Stefanie Lerche PostDoc
Clinical Parkinsons Disease Research
07071 29-80171 
 Katja Michaelis
Katja Michaelis study nurse
Clinical Parkinsons Disease Research
07071 29-80446 
 Gabriela Ragusa
Gabriela Ragusa
Clinical Parkinsons Disease Research
07071 29-81465 
Dr. Benjamin Roeben
Dr. Benjamin Roeben Physician
Clinical Parkinsons Disease Research
07071 29-80438 
 Claudia Schulte
Claudia Schulte PhD Student
Clinical Parkinsons Disease Research
07071 29-82041 
 Ina Wolfstädter
Ina Wolfstädter Parkinson Nurse
Clinical Parkinsons Disease Research
 
Dr. Isabel Wurster
Dr. Isabel Wurster Physician
Clinical Parkinsons Disease Research
07071 29-80171 
Dr. Milan Zimmermann
Dr. Milan Zimmermann Physican
Clinical Parkinsons Disease Research
 

Outpatient-Clinic Parkinson

The outpatient clinic for Parkinson’s disease covers not only the sporadic form of the disease but also atypical forms such as dementia with lewy bodies, multisystematrophie, progressive supranuclear gaze palsy, and corticobasal syndrome. Next to an accurate clinical diagnosis we focus on long-term evaluation and disease progression.

Publications since 2006

 

2019

Parkinsonism Relat Disord., pii: S1353-8020(18)30559-5 [Epub ahead of print]
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).

Prakash N, Caspell-Garcia C, Coffey C, Siderowf A, Tanner CM, Kieburtz K, Mollenhauer B, Galasko D, Merchant K, Foroud T, Chahine LM, Weintraub D, Casaceli C, Dorsey R, Wilson R, Herzog M, Daegele N, Arnedo V, Frasier M, Sherer T, Marek K, Simuni T; Parkinson's Progression Markers InitiativeSteering Committee; Study Cores; Site Investigators; Coordinators; Industry and Scientific Advisory Board.

Mov Disord, [Epub ahead of print]
The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease.
Bandres-Ciga S, Saez-Atienzar S, Bonet-Ponce L, Billingsley K, Vitale D, Blauwendraat C, Gibbs JR, Pihlstrøm L, Gan-Or Z; International Parkinson's Disease Genomics Consortium (IPDGC), Cookson MR, Nalls MA, Singleton AB.

Eur J Neurol. 2019 Apr;26(4):694-698
Patient's perception: shorter and more severe prodromal phase in GBA-associated PD.
Zimmermann M, Gaenslen A, Prahl K, Srulijes K, Hauser AK, Schulte C, Csoti I, Berg D, Brockmann K.** (**corresponding author)

Sci Rep. 2019 Mar 14;9(1):4515.
The Parkinson's disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4.
Funk N, Munz M, Ott T, Brockmann K, Wenninger-Weinzierl A, Kühn R, Vogt-Weisenhorn D, Giesert F, Wurst W, Gasser T, Biskup S.

J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):165-170
Parkinson's disease: evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study.
Lerche S, Wurster I, Röben B, Machetanz G, Zimmermann M, Bernhard F, Stransky E, Deuschle C, Schulte C, Hansson O, Zetterberg H, Gasser T, Berg D, Maetzler W, Brockmann K.

2018

Lancet Neurol.;17(12):1032.
LRP10 in α-synucleinopathies.
Kia DA, Sabir MS, Ahmed S, Trinh J, Bandres-Ciga S; International Parkinson's Disease Genomics Consortium.

Front Neurol., 9:1094.
Dermal Phospho-Alpha-Synuclein Deposition in Patients With Parkinson's Disease and Mutation of the Glucocerebrosidase Gene.
Doppler K, Brockmann K*, Sedghi A, Wurster I, Volkmann J, Oertel WH, Sommer C. (*contributed equally)

Oncotarget.,9(95):36732-36733.
REM sleep behaviour disorder (RBD): risk for Parkinsonism and executive dysfunction in elderly.
Lerche S, Brockmann K.

NeuroTransmitter 29(11):34-43
Assessment von Alltagsfunktionen und Therapie bei Parkinson-Demenz
Becker S, Brockmann K, Liepelt-Scarfone I.

J Neuropsychol, [Epub ahead of print]
Assessment of cognitive-driven activity of daily living impairment in non-demented Parkinson's patients.
Becker S, Bäumer A, Maetzler W, Nussbaum S, Timmers M, Van Nueten L, Salvadore G, Zaunbrecher D, Roeben B, Brockmann K, Streffer J, Berg D, Liepelt-Scarfone I.

Sci Rep.,8(1):12803.
Arm swing asymmetry in overground walking.
Killeen T, Elshehabi M, Filli L, Hobert MA, Hansen C, Rieger D, Brockmann K, Nussbaum S, Zörner B, Bolliger M, Curt A, Berg D, Maetzler W.

Mov Disord., 33(8):1349-1353
Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease.
Lerche S, Liepelt-Scarfone I, Wurster I, Schulte C, Schäffer E, Röben B, Machetanz G, Zimmermann M, Akbas S, Hauser AK, Gasser T, Maetzler W, Berg D, Brockmann K.** (**corresponding author)

Neurobiol Aging., 70:242-246.
Deterioration of executive dysfunction in elderly with REM sleep behavior disorder (RBD).
Lerche S, Machetanz G, Roeben B, Wurster I, Zimmermann M, von Thaler AK, Liepelt-Scarfone I, Eschweiler GW, Fallgatter A, Metzger F, Maetzler W, Berg D, Brockmann K.

Ann Clin Transl Neurol., 5(7):876-882.
Serum neurofilament light chain is increased in hereditary spastic paraplegias.
Wilke C, Rattay TW, Hengel H, Zimmermann M, Brockmann K, Schöls L, Kuhle J, Schüle R, Synofzik M.

J Neurol., 265(9):1976-1984.
Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson's disease patients.
Sulzer P, Becker S, Maetzler W, Kalbe E, van Nueten L, Timmers M, Machetanz G, Streffer J, Salvadore G, Scholz E, Tkaczynska Z, Brockmann K, Berg D, Liepelt-Scarfone I.

Parkinsonism Relat Disord., 55:145-147.
Biallelic Parkin (PARK2) mutations can cause a bvFTD phenotype without clinically relevant parkinsonism.
Zimmermann M, Wilke C, Schulte C, Hoffmann J, Klopfer J, Reimold M, Brockmann K, Synofzik M.

J Neurol., 265(7):1618-1624.
Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study.
Wilke C, Bender F, Hayer SN, Brockmann K, Schöls L, Kuhle J, Synofzik M.

Mov Disord., 33(6):1025-1027.
Age- and sex-related heterogeneity in prodromal Parkinson's disease.
Heinzel S, Kasten M, Behnke S, Vollstedt EJ, Klein C, Hagenah J, Pausch C, Heilmann R, Brockmann K, Suenkel U, Yilmaz R, Liepelt-Scarfone I, Walter U, Berg D.

Clin Neurol Neurosurg., 165:88-93.
Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly.
Lerche S, Gutfreund A, Brockmann K, Hobert MA, Wurster I, Sünkel U, Eschweiler GW, Metzger FG, Maetzler W, Berg D.

Biochem J., 475(1):23-44.
Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils.
Fan Y, Howden AJM, Sarhan AR, Lis P, Ito G, Martinez TN, Brockmann K, Gasser T, Alessi DR, Sammler EM.

2017

Brain., 140(12):3191-3203.
Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease.
Robak LA, Jansen IE, van Rooij J, Uitterlinden AG, Kraaij R, Jankovic J; International Parkinson’s Disease Genomics Consortium (IPDGC), Heutink P, Shulman JM.

Atten Defic Hyperact Disord., 9(2):121-127.
No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease in nine ADHD candidate SNPs.
Geissler JM; International Parkinson Disease Genomics Consortium members, Romanos M, Gerlach M, Berg D, Schulte C.

Genome Biol., 18(1):22.
Discovery and functional prioritization of Parkinson's disease candidate genes from large-scale whole exome sequencing.
Jansen IE, Ye H, Heetveld S, Lechler MC, Michels H, Seinstra RI, Lubbe SJ, Drouet V, Lesage S, Majounie E, Gibbs JR, Nalls MA, Ryten M, Botia JA, Vandrovcova J, Simon-Sanchez J, Castillo-Lizardo M, Rizzu P, Blauwendraat C, Chouhan AK, Li Y, Yogi P, Amin N, van Duijn CM; International Parkinson’s Disease Genetics Consortium (IPGDC), Morris HR, Brice A, Singleton AB, David DC, Nollen EA, Jain S, Shulman JM, Heutink P.

Mov Disord. 2017 Dec;32(12):1655-1666.
Cognitive changes in prodromal Parkinson's disease: A review.
Fengler S, Liepelt-Scarfone I, Brockmann K, Schäffer E, Berg D, Kalbe E.

Neurology. 2017 Dec 5;89(23):2335-2340. doi: 10.1212/WNL.0000000000004705. Epub 2017 Nov 8.
SNPs in Aβ clearance proteins: Lower CSF Aβ1-42 levels and earlier onset of dementia in PD.
Brockmann K, Lerche S, Dilger SS, Stirnkorb JG, Apel A, Hauser AK, Liepelt-Scarfone I, Berg D, Gasser T, Schulte C, Maetzler W.

Mov Disord. 2017 Dec;32(12):1655-1666. doi: 10.1002/mds.27135. Epub 2017 Oct 5.
Cognitive changes in prodromal Parkinson's disease: A review.
Fengler S, Liepelt-Scarfone I, Brockmann K, Schäffer E, Berg D, Kalbe E.

Mov Disord. 2017 Dec;32(12):1780-1783. doi: 10.1002/mds.27199. Epub 2017 Nov 2.
Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles.
Lerche S, Schulte C, Srulijes K, Pilotto A, Rattay TW, Hauser AK, Stransky E, Deuschle C, Csoti I, Lachmann I, Zetterberg H, Liepelt-Scarfone I, Gasser T, Maetzler W, Berg D, Brockmann K.

Eur J Neurol. 2017 Nov;24(11):1369-1374. doi: 10.1111/ene.13397. Epub 2017 Sep 5.
Progression of prodromal motor and non-motor symptoms in the premotor phase study - 2-year follow-up data.
Liepelt-Scarfone I, Brändle B, Yilmaz R, Gauss K, Schaeffer E, Timmers M, Wurster I, Brockmann K, Maetzler W, Van Nueten L, Streffer JR, Berg D.

Mov Disord. 2017 Oct;32(10):1401-1408. doi: 10.1002/mds.27132. Epub 2017 Aug 26.
Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease.
Trezzi JP, Galozzi S, Jaeger C, Barkovits K, Brockmann K, Maetzler W, Berg D, Marcus K, Betsou F, Hiller K, Mollenhauer B.

Mov Disord. 2017 Oct;32(10):1432-1438. doi: 10.1002/mds.27059. Epub 2017 Jun 22.
Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
Lee AJ, Wang Y, Alcalay RN, Mejia-Santana H, Saunders-Pullman R, Bressman S, Corvol JC, Brice A, Lesage S, Mangone G, Tolosa E, Pont-Sunyer C, Vilas D, Schüle B, Kausar F, Foroud T, Berg D, Brockmann K, Goldwurm S, Siri C, Asselta R, Ruiz-Martinez J, Mondragón E, Marras C, Ghate T, Giladi N, Mirelman A, Marder K; Michael J. Fox LRRK2 Cohort Consortium.

Brain. 2017 Sep 1;140(9):2444-2459. doi: 10.1093/brain/awx202.
Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease.
Fitzgerald JC, Zimprich A, Carvajal Berrio DA, Schindler KM, Maurer B, Schulte C, Bus C, Hauser AK, Kübler M, Lewin R, Bobbili DR, Schwarz LM, Vartholomaiou E, Brockmann K, Wüst R, Madlung J, Nordheim A, Riess O, Martins LM, Glaab E, May P, Schenke-Layland K, Picard D, Sharma M, Gasser T, Krüger R.

Parkinsons Dis. 2017;2017:8582740. doi: 10.1155/2017/8582740. Epub 2017 Jul 27.
Dual-Task Performance in GBA Parkinson's Disease.
Srulijes K, Brockmann K, Ogbamicael S, Hobert MA, Hauser AK, Schulte C, Fritzen J, Schwenk M, Gasser T, Berg D, Maetzler W.

Nervenarzt. 2017 Jul;88(7):713-719. doi: 10.1007/s00115-017-0348-5.
[Genetic risk variants in Parkinson's disease and other movement disorders].
[Article in German]Brockmann K, Lohmann K.

Mov Disord. 2017 Jul;32(7):1025-1034. doi: 10.1002/mds.27035. Epub 2017 May 16.
Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts.
Pilotto A, Heinzel S, Suenkel U, Lerche S, Brockmann K, Roeben B, Schaeffer E, Wurster I, Yilmaz R, Liepelt-Scarfone I, von Thaler AK, Metzger FG, Eschweiler GW, Postuma RB, Maetzler W, Berg D.

Eur J Neurol. 2017 Feb;24(2):427-e6. doi: 10.1111/ene.13223.
Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease.
Brockmann K, Schulte C, Schneiderhan-Marra N, Apel A, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Bernard A, Gasser T, Marras C, Schüle B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Berg D, Maetzler W.

Genome Biol. 2017 Jan 30;18(1):22. doi: 10.1186/s13059-017-1147-9.
Discovery and functional prioritization of Parkinson's disease candidate genes from large-scale whole exome sequencing.
Jansen IE, Ye H, Heetveld S, Lechler MC, Michels H, Seinstra RI, Lubbe SJ, Drouet V, Lesage S, Majounie E, Gibbs JR, Nalls MA, Ryten M, Botia JA, Vandrovcova J, Simon-Sanchez J, Castillo-Lizardo M, Rizzu P, Blauwendraat C, Chouhan AK, Li Y, Yogi P, Amin N, van Duijn CM; International Parkinson’s Disease Genetics Consortium (IPGDC), Morris HR, Brice A, Singleton AB, David DC, Nollen EA, Jain S, Shulman JM, Heutink P.

2016

Am J Hum Genet., 98(3):500-513.
Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy.
Lesage S, Drouet V, Majounie E, Deramecourt V, Jacoupy M, Nicolas A, Cormier-Dequaire F, Hassoun SM, Pujol C, Ciura S, Erpapazoglou Z, Usenko T, Maurage CA, Sahbatou M, Liebau S, Ding J, Bilgic B, Emre M, Erginel-Unaltuna N, Guven G, Tison F, Tranchant C, Vidailhet M, Corvol JC, Krack P, Leutenegger AL, Nalls MA, Hernandez DG, Heutink P, Gibbs JR, Hardy J, Wood NW, Gasser T, Durr A, Deleuze JF, Tazir M, Destée A, Lohmann E, Kabashi E, Singleton A, Corti O, Brice A; French Parkinson's Disease Genetics Study (PDG); International Parkinson's Disease Genomics Consortium (IPDGC).

Alzheimers Res Ther. 2016 Oct 10;8(1):42.
Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs.
Lerche S, Brockmann K, Pilotto A, Wurster I, Sünkel U, Hobert MA, von Thaler AK, Schulte C, Stoops E, Vanderstichele H, Herbst V, Brix B, Eschweiler GW, Metzger FG, Maetzler W, Berg D.

Mov Disord. 2016 Oct;31(10):1527-1534. doi: 10.1002/mds.26720.
Arm swing as a potential new prodromal marker of Parkinson's disease.
Mirelman A, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, Gurevich T, Gana-Weisz M, Saunders-Pullman R, Raymond D, Doan N, Bressman SB, Marder KS, Alcalay RN, Rao AK, Berg D, Brockmann K, Aasly J, Waro BJ, Tolosa E, Vilas D, Pont-Sunyer C, Orr-Urtreger A, Hausdorff JM, Giladi N.

Parkinsonism Relat Disord. 2016 Oct;31:148-150. doi: 10.1016/j.parkreldis.2016.07.005. Epub 2016 Jul 15.
Broad clinical phenotype in Parkinsonism associated with a base pair deletion in RAB39B and additional POLG variant.
Güldner M, Schulte C, Hauser AK, Gasser T, Brockmann K.

Mov Disord. 2016 Jun;31(6):906-14. doi: 10.1002/mds.26591. Epub 2016 Apr 4.
Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D, Shaw LM, Taylor P, Berg D, Brockmann K, Aasly J, Marras C, Pont-Sunyer C, Ríos J, Marek K, Tolosa E.

J Neuroinflammation. 2016 May 24;13(1):122. doi: 10.1186/s12974-016-0588-5.
Inflammatory profile in LRRK2-associated prodromal and clinical PD.
Brockmann K, Apel A, Schulte C, Schneiderhan-Marra N, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Gasser T, Schüle B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Marras C, Berg D, Maetzler W.

Lancet Neurol. 2016 May;15(6):585-96. doi: 10.1016/S1474-4422(16)00071-5. Epub 2016 Mar 24.
Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data.
Mok KY, Sheerin U, Simón-Sánchez J, Salaka A, Chester L, Escott-Price V, Mantripragada K, Doherty KM, Noyce AJ, Mencacci NE, Lubbe SJ; International Parkinson's Disease Genomics Consortium (IPDGC), Williams-Gray CH, Barker RA, van Dijk KD, Berendse HW, Heutink P, Corvol JC, Cormier F, Lesage S, Brice A, Brockmann K, Schulte C, Gasser T, Foltynie T, Limousin P, Morrison KE, Clarke CE, Sawcer S, Warner TT, Lees AJ, Morris HR, Nalls MA, Singleton AB, Hardy J, Abramov AY, Plagnol V, Williams NM, Wood NW.

Mov Disord. 2016 Apr;31(4):601-3. doi: 10.1002/mds.26558. Epub 2016 Feb 16.
Alpha-synuclein gene variants may predict neurostimulation outcome.
Weiss D, Herrmann S, Wang L, Schulte C, Brockmann K, Plewnia C, Gasser T, Sharma M, Gharabaghi A, Krüger R.

PLoS One. 2016 Mar 3;11(3):e0149349. doi: 10.1371/journal.pone.0149349. eCollection 2016.
GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia.
Maetzler W, Deleersnijder W, Hanssens V, Bernard A, Brockmann K, Marquetand J, Wurster I, Rattay TW, Roncoroni L, Schaeffer E, Lerche S, Apel A, Deuschle C, Berg D.

Eur J Neurol. 2016 Mar;23(3):520-6. doi: 10.1111/ene.12894. Epub 2015 Nov 9.
GBA-associated parkinsonism and dementia: beyond α-synucleinopathies?
Pilotto A, Schulte C, Hauser AK, Biskup S, Munz M, Brockmann K, Schaeffer E, Synofzik M, Maetzler W, Suenkel U, Srulijes K, Gasser T, Berg D.

2015

Neurobiol Aging., 36(3):1605.e7-12.
NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases
Nalls MA, Bras J, Hernandez DG, Keller MF, Majounie E, Renton AE, Saad M, Jansen I, Guerreiro R, Lubbe S, Plagnol V, Gibbs JR, Schulte C, Pankratz N, Sutherland M, Bertram L, Lill CM, DeStefano AL, Faroud T, Eriksson N, Tung JY, Edsall C, Nichols N, Brooks J, Arepalli S, Pliner H, Letson C, Heutink P, Martinez M, Gasser T, Traynor BJ, Wood N, Hardy J, Singleton AB; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Disease meta-analysis consortium.

Mol Psychiatry., 20(5):647-656.
Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption.
Coffee and Caffeine Genetics Consortium, Cornelis MC, Byrne EM, Esko T, Nalls MA, Ganna A, Paynter N, Monda KL, Amin N, Fischer K, Renstrom F, Ngwa JS, Huikari V, Cavadino A, Nolte IM, Teumer A, Yu K, Marques-Vidal P, Rawal R, Manichaikul A, Wojczynski MK, Vink JM, Zhao JH, Burlutsky G, Lahti J, Mikkilä V, Lemaitre RN, Eriksson J, Musani SK, Tanaka T, Geller F, Luan J, Hui J, Mägi R, Dimitriou M, Garcia ME, Ho WK, Wright MJ, Rose LM, Magnusson PK, Pedersen NL, Couper D, Oostra BA, Hofman A, Ikram MA, Tiemeier HW, Uitterlinden AG, van Rooij FJ, Barroso I, Johansson I, Xue L, Kaakinen M, Milani L, Power C, Snieder H, Stolk RP, Baumeister SE, Biffar R, Gu F, Bastardot F, Kutalik Z, Jacobs DR Jr, Forouhi NG, Mihailov E, Lind L, Lindgren C, Michaëlsson K, Morris A, Jensen M, Khaw KT, Luben RN, Wang JJ, Männistö S, Perälä MM, Kähönen M, Lehtimäki T, Viikari J, Mozaffarian D, Mukamal K, Psaty BM, Döring A, Heath AC, Montgomery GW, Dahmen N, Carithers T, Tucker KL, Ferrucci L, Boyd HA, Melbye M, Treur JL, Mellström D, Hottenga JJ, Prokopenko I, Tönjes A, Deloukas P, Kanoni S, Lorentzon M, Houston DK, Liu Y, Danesh J, Rasheed A, Mason MA, Zonderman AB, Franke L, Kristal BS; International Parkinson’s Disease Genomics Consortium (IPDGC); North American Brain Expression Consortium (NABEC); UK Brain Expression Consortium (UKBEC), Karjalainen J, Reed DR, Westra HJ, Evans MK, Saleheen D, Harris TB, Dedoussis G, Curhan G, Stumvoll M, Beilby J, Pasquale LR, Feenstra B, Bandinelli S, Ordovas JM, Chan AT, Peters U, Ohlsson C, Gieger C, Martin NG, Waldenberger M, Siscovick DS, Raitakari O, Eriksson JG, Mitchell P, Hunter DJ, Kraft P, Rimm EB, Boomsma DI, Borecki IB, Loos RJ, Wareham NJ, Vollenweider P, Caporaso N, Grabe HJ, Neuhouser ML, Wolffenbuttel BH, Hu FB, Hyppönen E, Järvelin MR, Cupples LA, Franks PW, Ridker PM, van Duijn CM, Heiss G, Metspalu A, North KE, Ingelsson E, Nettleton JA, van Dam RM, Chasman DI.

Parkinsonism Relat Disord., 21(12):1427-34
Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
Brockmann K**, Schulte C, Deuschle C, Hauser AK, Heger T, Gasser T, Maetzler W, Berg D. (**corresponding author)

BMC Neurol., 15:192.
Association between vestibulo-ocular reflex suppression, balance, gait, and fall risk in ageing and neurodegenerative disease: protocol of a one-year prospective follow-up study.
Srulijes K, Mack DJ, Klenk J, Schwickert L, Ihlen EA, Schwenk M, Lindemann U, Meyer M, Srijana KC, Hobert MA, Brockmann K, Wurster I, Pomper JK, Synofzik M, Schneider E, Ilg U, Berg D, Maetzler W, Becker C.

PLoS One., 10(9):e0138863.
Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying Verbal Fluency.
Heinzel S, Metzger FG, Ehlis AC, Korell R, Alboji A, Haeussinger FB, Wurster I, Brockmann K, Suenkel U, Eschweiler GW, Maetzler W, Berg D, Fallgatter AJ.

Brain., 138(Pt 11):3316-26.
No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra.
Schöls L, Reimold M, Seidel K, Globas C, Brockmann K, Hauser TK, Auburger G, Bürk K, den Dunnen W, Reischl G, Korf HW, Brunt ER, Rüb U.

Parkinsonism Relat Disord., 21(2):126-30.
Reasons for mild parkinsonian signs - which constellation may indicate neurodegeneration?
Lerche S, Brockmann K, Wurster I, Gaenslen A, Roeben B, Holz D, Eschweiler GW, Maetzler W, Berg D.

J Neurol., 262(2):451-8.
Clinical characteristics related to worsening of motor function assessed by the Unified Parkinson's Disease Rating Scale in the elderly population.
Liepelt-Scarfone I, Lerche S, Behnke S, Godau J, Gaenslen A, Pausch C, Fassbender K, Brockmann K, Srulijes K, Huber H, Wurster I, Berg D.

Mov Disord., 30(3):407-11.
GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study.
Brockmann K**, Srulijes K, Pflederer S, Hauser AK, Schulte C, Maetzler W, Gasser T, Berg D. (**corresponding author)

J Med Genet., 52(1):37-41.
EIF4G1 is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts.
Huttenlocher J, Krüger R, Capetian P, Lohmann K, Brockmann K, Csoti I, Klein C, Berg D, Gasser T, Bonin M, Riess O, Bauer P.

2014

Nat Genet., 46(9):989-93
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.
Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI); 23andMe; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson's Disease Consortium; Alzheimer Genetic Analysis Group, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB.

Neurobiol Aging., 35(6):1512.e5-1512.e10.
Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease.
Dong J, Gao J, Nalls M, Gao X, Huang X, Han J, Singleton AB, Chen H; International Parkinson’s Disease Genomics Consortium (IPDGC).

Hum Mol Genet., 23(3):831-41
Genetic comorbidities in Parkinson's disease.
Nalls MA, Saad M, Noyce AJ, Keller MF, Schrag A, Bestwick JP, Traynor BJ, Gibbs JR, Hernandez DG, Cookson MR, Morris HR, Williams N, Gasser T, Heutink P, Wood N, Hardy J, Martinez M, Singleton AB; International Parkinson's Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC).

Genet Med. 2014 Aug;16(8):644-5
Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants.
Alcalay RN, Aasly J, Berg D, Bressman S, Brice A, Brockmann K, Chan P, Clark L, Cormier F, Corvol JC, Durr A, Facheris M, Farrer M, Foroud TM, Gasser T, Giladi N, Halter C, Lang A, Langston JW, Marras C, Marti-Masso JF, Ruiz Martinez J, Mejia-Santana H, Mirelman A, Pont-Sunyer C, Orr-Urtreger A, Raymond D, Saunders-Pullman R, Schüle B, Tanner C, Tolosa E, Urkowitz A, Vilas D, Wise A, Marder K.

Front Aging Neurosci. 2014 Jul 9;6:161.
A neurodegenerative vascular burden index and the impact on cognition.
Heinzel S, Liepelt-Scarfone I, Roeben B, Nasi-Kordhishti I, Suenkel U, Wurster I, Brockmann K, Fritsche A, Niebler R, Metzger FG, Eschweiler GW, Fallgatter AJ, Maetzler W, Berg D.

J Inherit Metab Dis. 2014 Jul;37(4):643-8.
The significance of GBA for Parkinson's disease.
Brockmann K**, Berg D (**corresponding author)

Eur J Neurol. 2014 May;21(5):766-72.
Prodromal features for Parkinson's disease--baseline data from the TREND study.
Gaenslen A, Wurster I, Brockmann K, Huber H, Godau J, Faust B, Lerche S, Eschweiler GW, Maetzler W, Berg D.

J Neurol. 2014 May;261(5):884-8.
Parkinson's disease with and without preceding essential tremor-similar phenotypes: a pilot study.
Wurster I, Abaza A, Brockmann K, Liepelt-Scarfone I, Berg D.

PLoS One. 2014 Mar 27;9(3):e92878.
Mild parkinsonian signs in the elderly--is there an association with PD? Crossectional findings in 992 individuals.
Lerche S, Hobert M, Brockmann K, Wurster I, Gaenslen A, Hasmann S, Eschweiler GW, Maetzler W, Berg D.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2626-31.
Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.
Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, Kalia LV, Lobbestael E, Chia R, Ndukwe K, Ding J, Nalls MA; International Parkinson’s Disease Genomics Consortium; North American Brain Expression Consortium, Olszewski M, Hauser DN, Kumaran R, Lozano AM, Baekelandt V, Greene LE, Taymans JM, Greggio E, Cookson MR.

Antioxid Redox Signal., 20(13):1955-60
Does uncoupling protein 2 expression qualify as marker of disease status in LRRK2-associated Parkinson's disease?
Grünewald A, Arns B, Meier B, Brockmann K, Tadic V, Klein C.

J Neurol., 261(1):180-7
Risk factors and prodromal markers and the development of Parkinson's disease.
Lerche S, Seppi K, Behnke S, Liepelt-Scarfone I, Godau J, Mahlknecht P, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Poewe W, Berg D.

2013

JAMA Neurol., 70(10):1268-76.
Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk.
Moskvina V, Harold D, Russo G, Vedernikov A, Sharma M, Saad M, Holmans P, Bras JM, Bettella F, Keller MF, Nicolaou N, Simón-Sánchez J, Gibbs JR, Schulte C, Durr A, Guerreiro R, Hernandez D, Brice A, Stefánsson H, Majamaa K, Gasser T, Heutink P, Wood N, Martinez M, Singleton AB, Nalls MA, Hardy J, Owen MJ, O'Donovan MC, Williams J, Morris HR, Williams NM; IPDGC and GERAD Investigators.

PLoS Med., 10(6):e1001462.
Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study.
Pichler I, Del Greco M F, Gögele M, Lill CM, Bertram L, Do CB, Eriksson N, Foroud T, Myers RH; PD GWAS Consortium, Nalls M, Keller MF; International Parkinson's Disease Genomics Consortium; Wellcome Trust Case Control Consortium 2, Benyamin B, Whitfield JB; Genetics of Iron Status Consortium, Pramstaller PP, Hicks AA, Thompson JR, Minelli C.

J Neurol Neurosurg Psychiatry., 84(6):666-73.
The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism.
Klebe S, Golmard JL, Nalls MA, Saad M, Singleton AB, Bras JM, Hardy J, Simon-Sanchez J, Heutink P, Kuhlenbäumer G, Charfi R, Klein C, Hagenah J, Gasser T, Wurster I, Lesage S, Lorenz D, Deuschl G, Durif F, Pollak P, Damier P, Tison F, Durr A, Amouyel P, Lambert JC, Tzourio C, Maubaret C, Charbonnier-Beaupel F, Tahiri K, Vidailhet M, Martinez M, Brice A, Corvol JC; French Parkinson's Disease Genetics Study Group; International Parkinson's Disease Genomics Consortium (IPDGC).

Hum Mol Genet., 22(5):1039-49.
A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease.
Holmans P, Moskvina V, Jones L, Sharma M; International Parkinson's Disease Genomics Consortium, Vedernikov A, Buchel F, Saad M, Bras JM, Bettella F, Nicolaou N, Simón-Sánchez J, Mittag F, Gibbs JR, Schulte C, Durr A, Guerreiro R, Hernandez D, Brice A, Stefánsson H, Majamaa K, Gasser T, Heutink P, Wood NW, Martinez M, Singleton AB, Nalls MA, Hardy J, Morris HR, Williams NM.

Mov Disord., 28(9):1217-21.
SNCA: major genetic modifier of age at onset of Parkinson's disease.
Brockmann K**, Schulte C, Hauser AK, Lichtner P, Huber H, Maetzler W, Berg D, Gasser T.  (**corresponding author)

JAMA Neurol., 70(6):727-35
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies.
Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF, Morris CM, Theuns J, Crosiers D, Cras P, Engelborghs S, De Deyn PP, Van Broeckhoven C, Mann DM, Snowden J, Pickering-Brown S, Halliwell N, Davidson Y, Gibbons L, Harris J, Sheerin UM, Bras J, Hardy J, Clark L, Marder K, Honig LS, Berg D, Maetzler W, Brockmann K, Gasser T, Novellino F, Quattrone A, Annesi G, De Marco EV, Rogaeva E, Masellis M, Black SE, Bilbao JM, Foroud T, Ghetti B, Nichols WC, Pankratz N, Halliday G, Lesage S, Klebe S, Durr A, Duyckaerts C, Brice A, Giasson BI, Trojanowski JQ, Hurtig HI, Tayebi N, Landazabal C, Knight MA, Keller M, Singleton AB, Wolfsberg TG, Sidransky E.

Eur J Neurol., 20(4):e61-2.
No association of GBA mutations and multiple system atrophy.
Srulijes K, Hauser AK, Guella I, Asselta R, Brockmann K, Schulte C, Soldà G, Cilia R, Maetzler W, Schols L, Wenning GK, Poewe W, Barone P, Wüllner U, Oertel W, Berg D, Goldwurm S, Gasser T.

Cell Stem Cell., 12(3):354-67.
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.
Reinhardt P, Schmid B, Burbulla LF, Schöndorf DC, Wagner L, Glatza M, Höing S, Hargus G, Heck SA, Dhingra A, Wu G, Müller S, Brockmann K, Kluba T, Maisel M, Krüger R, Berg D, Tsytsyura Y, Thiel CS, Psathaki OE, Klingauf J, Kuhlmann T, Klewin M, Müller H, Gasser T, Schöler HR, Sterneckert J.

Nervenarzt., 84(2):143-50
Genetics of movement disorders
Lohmann K, Brockmann K.

Neurobiol Dis., 54:280-8.
Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration.
Caesar M, Zach S, Carlson CB, Brockmann K, Gasser T, Gillardon F.

Parkinsonism Relat Disord., 19(3):371-4.
How precise are activities of daily living scales for the diagnosis of Parkinson's disease dementia? A pilot study.
Christ JB, Fruhmann Berger M, Riedl E, Prakash D, Csoti I, Molt W, Gräber S, Brockmann K, Berg D, Liepelt-Scarfone I.

2012

Hum Mol Genet., 21(22):4996-5009.
Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease.
Keller MF, Saad M, Bras J, Bettella F, Nicolaou N, Simón-Sánchez J, Mittag F, Büchel F, Sharma M, Gibbs JR, Schulte C, Moskvina V, Durr A, Holmans P, Kilarski LL, Guerreiro R, Hernandez DG, Brice A, Ylikotila P, Stefánsson H, Majamaa K, Morris HR, Williams N, Gasser T, Heutink P, Wood NW, Hardy J, Martinez M, Singleton AB, Nalls MA; International Parkinson's Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2).

Hum Mutat., 33(12):1708-18.
Use of support vector machines for disease risk prediction in genome-wide association studies: concerns and opportunities.
Mittag F, Büchel F, Saad M, Jahn A, Schulte C, Bochdanovits Z, Simón-Sánchez J, Nalls MA, Keller M, Hernandez DG, Gibbs JR, Lesage S, Brice A, Heutink P, Martinez M, Wood NW, Hardy J, Singleton AB, Zell A, Gasser T, Sharma M; International Parkinson’s Disease Genomics Consortium.

Int J Alzheimers Dis., 2012:910757.
Cognitive profiles in Parkinson's disease and their relation to dementia: a data-driven approach.
Liepelt-Scarfone I, Gräber S, Fruhmann Berger M, Feseker A, Baysal G, Csoti I, Godau J, Gaenslen A, Huber H, Srulijes K, Brockmann K, Berg D.

Mov Disord., 28(2):216-9.
Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease.
Berg D, Behnke S, Seppi K, Godau J, Lerche S, Mahlknecht P, Liepelt-Scarfone I, Pausch C, Schneider N, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Gasser T, Poewe W.

Proteomics Clin Appl., 6(9-10):497-501
Stepwise isolation of human peripheral erythrocytes, T lymphocytes, and monocytes for blood cell proteomics.
Brosseron F, May C, Schoenebeck B, Tippler B, Woitalla D, Kauth M, Brockmann K, Meyer HE, Berg D, Bufe A, Marcus K.

J Alzheimers Dis., 32(1):95-100
Lowered serum amyloid-β1-42 autoantibodies in individuals with lifetime depression.
Maetzler W, Langkamp M, Lerche S, Godau J, Brockmann K, Gaenslen A, Huber H, Wurster I, Niebler R, Eschweiler GW, Berg D.

Neurology., 79(3):213-20.
GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure.
Brockmann K, Hilker R, Pilatus U, Baudrexel S, Srulijes K, Magerkurth J, Hauser AK, Schulte C, Csoti I, Merten CD, Gasser T, Berg D, Hattingen E.

J Nucl Med., 53(7):1074-80
PET and MRI reveal early evidence of neurodegeneration in spinocerebellar ataxia type 17.
Brockmann K*, Reimold M*, Globas C, Hauser TK, Walter U, Machulla HJ, Rolfs A, Schöls L. (*equally contributed)

J Neurol., 259(9):1970-2.
Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinson's disease.
Weiss D, Brockmann K, Srulijes K, Meisner C, Klotz R, Reinbold S, Hauser AK, Schulte C, Berg D, Gasser T, Plewnia C, Gharabaghi A, Breit S, Wächter T, Krüger R.

Mov Disord., 27(2):288-92
Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease.
Schmid SP, Schleicher ED, Cegan A, Deuschle C, Baur S, Hauser AK, Synofzik M, Srulijes K, Brockmann K, Berg D, Maetzler W.

2011

PLoS Genet., 7(6):e1002142.
A two-stage meta-analysis identifies several new loci for Parkinson's disease.
International Parkinson's Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2).

Lancet., 377(9766):641-9.
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.
International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simón-Sánchez J, Schulte C, Lesage S, Sveinbjörnsdóttir S, Stefánsson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW.

PLoS One., 6(11):e27831
Poor trail making test performance is directly associated with altered dual task prioritization in the elderly--baseline results from the TREND study.
Hobert MA, Niebler R, Meyer SI, Brockmann K, Becker C, Huber H, Gaenslen A, Godau J, Eschweiler GW, Berg D, Maetzler W.

Mov Disord., 26(13):2335-42.
Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
Brockmann K**, Gröger A, Di Santo A, Liepelt I, Schulte C, Klose U, Maetzler W, Hauser AK, Hilker R, Gomez-Mancilla B, Berg D, Gasser T.  (**corresponding author)

Arch Neurol., 68(7):925-31.
Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease.
Godau J, Knauel K, Weber K, Brockmann K, Maetzler W, Binder G, Berg D.

Neurology., 77(3):276-80.
GBA-associated PD presents with nonmotor characteristics.
Brockmann K**, Srulijes K, Hauser AK, Schulte C, Csoti I, Gasser T, Berg D. (**corresponding author)

J Alzheimers Dis., 26(1):171-9.
Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.
Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, Gasser T, Hörnig S, Langkamp M.

PLoS One., 6(1):e15125.
CAG repeats determine brain atrophy in spinocerebellar ataxia 17: a VBM study.
Reetz K, Kleiman A, Klein C, Lencer R, Zuehlke C, Brockmann K, Rolfs A, Binkofski F.

Neurology., 77(9):914.
Rapid emergence of temporal and pulvinar lesions in MELAS mimicking Creutzfeldt-Jakob disease.
Weiss D, Brockmann K, Nägele T, Gasser T, Krüger R.

2010

J Alzheimers Dis., 22(3):933-8.
Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in Lewy body disease.
Maetzler W, Stoycheva V, Schmid B, Schulte C, Hauser AK, Brockmann K, Melms A, Gasser T, Berg D.

J Alzheimers Dis., 19(3):937-42.
The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease.
Maetzler W, Schmid B, Synofzik M, Schulte C, Riester K, Huber H, Brockmann K, Gasser T, Berg D, Melms A.

Cerebellum., 9(2):210-7
Structural changes associated with progression of motor deficits in spinocerebellar ataxia 17.
Reetz K, Lencer R, Hagenah JM, Gaser C, Tadic V, Walter U, Wolters A, Steinlechner S, Zühlke C, Brockmann K, Klein C, Rolfs A, Binkofski F.

Int Rev Neurobiol. 2010;90:157-64.
TCS in monogenic forms of Parkinson's disease.
Brockmann K, Hagenah J.

2006

Brain., 129(Pt 9):2341-52.
Morphological basis for the spectrum of clinical deficits in spinocerebellar ataxia 17 (SCA17).

Lasek K, Lencer R, Gaser C, Hagenah J, Walter U, Wolters A, Kock N, Steinlechner S, Nagel M, Zühlke C, Nitschke MF, Brockmann K, Klein C, Rolfs A, Binkofski F.

Junior research group leader
Dr. Kathrin Brockmann kathrin.brockmannuni-tuebingen.de Address

Center of Neurology
Hertie Institute for Clinical Brain Research
Department Neurodegenerative Diseases

Hoppe-Seyler-Straße 3
72076 Tübingen

Fax: +49 (0)7071 29-4490